Alexandria Real Estate Equities, Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 557 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• SELF-GATE (computed on this final file, chart arithmetic): 13 register rows, raw share sum 102,984,209, less 562,724 double-counted in the 'Executive officers and directors as a group' container (reduced to its 1,776,993-share residual) = 102,421,485 charted shares / 174,247,570 shares outstanding = 58.78%. This is above the brief's 55% flag threshold, so it was corroborated per holder rather than accepted on implied-price consistency alone: (1) every non-Vanguard, non-JPMorgan, non-Capital-Group row was independently re-verified against this project's own 31 Mar 2026 data/registers/ARE.json snapshot and lands within a normal single-quarter move of the snapshot figure (Vanguard family +0.9%, BlackRock +10.2%, State Street -0.6%, Invesco +3.7%, APG unchanged, Geode +2.4%, T. Rowe Associates -5.6%); (2) the register snapshot's own total_shares_reported (148,604,161 as of 31 Mar 2026, across 557 filers) is 85.3% of the 174,247,570-share denominator used here, indicating ARE is a heavily institutionally held REIT, consistent with a concentrated top-13 in the high-50s percent range rather than an error; (3) two of the proxy's own Five Percent Stockholder rows were back-solved as an independent denominator check: Vanguard 25,820,691 sh / 14.91% implies 173,177,010 shares outstanding, and BlackRock 20,291,782 sh / 11.72% implies 173,138,242 shares outstanding, both landing within about 0.6% of the proxy's own stated 173,127,082-share denominator (16 Mar 2026) and reasonably close to the newer 174,247,570-share cover-page figure used throughout this file (15 Jul 2026, after several months of ATM equity issuance, which a REIT like ARE runs continuously; this explains the gap rather than indicating an error). The two rows driving the total above 55% (JPMorgan down about 61% quarter over quarter, and Capital Group family dropping from 3,234,872 shares in Q1 to a fully verified ZERO in Q2) were each independently re-fetched and re-read directly from their live Q2 2026 13F-HR/no-position filings (not taken from the snapshot or from an aggregator), including a raw-text grep confirming CUSIP 015271109 is entirely absent from Capital World Investors' Q2 2026 information table, so both moves are treated as real rather than as pipeline artifacts.
• Capital Group family (Capital World Investors CIK 0001422849, Capital International Investors CIK 0001562230, Capital Research Global Investors CIK 0001422848, Capital International Sarl CIK 0001065349) was checked in full for Q2 2026 (period 2026-06-30) and reports ZERO ARE shares across all four registrants, versus 3,234,872 shares (1.86%) in the 31 Mar 2026 register snapshot. This is recorded here as a note, not a row, per the project's rule that a holder checked and found at zero is a note rather than a null row.
• Cohen & Steers, Inc. (CIK 0001284812) and Cohen & Steers Capital Management Inc (CIK 0000845563, dormant/no recent 13F activity found) were checked given the project's specific flag that Cohen & Steers shows up heavily on REITs; Cohen & Steers, Inc.'s Q2 2026 13F-HR reports ZERO ARE shares. Recorded as a note, not a row.
• T. Rowe Price Investment Management, Inc. (CIK 0001897612), the separate registrant the project specifically flags as sometimes holding a proxy's 5% position instead of T. Rowe Price Associates, was checked for Q2 2026 and reports ZERO ARE shares; only Associates (CIK 0000080255) holds. Recorded as a note.
• Alexandria runs a large life-science venture-investment arm (branded 'Alexandria Venture Investments' / AVI in its own SEC ownership filings, though that name does not appear anywhere in the 10-K or 10-Q text searched). Per the Q2 2026 10-Q (Note 7, 'Investments'), ARE's non-real-estate investment portfolio totaled $1,685,695 thousand in fair value as of 30 Jun 2026 (versus $1,501,249 thousand at 31 Dec 2025), of which 'Investments in publicly traded companies' (fair-value, readily-determinable-value instruments) was a COMBINED balance of $122,812 thousand ($122.812 million) as of 30 Jun 2026, disclosed only in a liquidity-availability table; investments accounted for under the equity method (mostly private) were $397,445 thousand; the remaining balance is privately held entities that do report or do not report NAV. Gross unrealized gains on the whole non-real-estate portfolio were $290.5 million as of 30 Jun 2026. A Public/Private Mix table (on a cost basis) shows only 6% Public / 94% Private. Neither the 10-Q nor the FY2025 10-K names any individual public-company investee or gives an investee-level dollar figure or share count anywhere in the body text searched; per the project's rule against assigning a combined balance to one investee, none of this $122.812 million public-company balance, nor the $397.445 million equity-method balance, nor the $1.6857 billion grand total, is assigned to Applied Therapeutics or to any other single name. Only Applied Therapeutics is individually sized in this file, and only because ARE separately filed a Schedule 13G/A naming it specifically (not from the 10-Q/10-K).
• Exhibit 21 (subsidiaries list) of the FY2025 10-K was checked per the project's technique of looking for an ownership-percentage column; it is a bare name list with no percentage column (a genuine negative), though it does confirm the existence of the 'Alexandria Venture Investments, LLC' subsidiary and separately list many single-property real estate subsidiary LLCs without percentages.
• ARE itself files no Form 13F (confirmed via EDGAR browse-edgar, CIK 0001035443, type=13F: zero results), so its own SC 13D/13G filings on individual biotech investees are the best available primary source for named public holdings, per the project's exception for filers that do not file a 13F. The full list of ARE's SC 13(D/G) filings (either direction) was reviewed back to 2019; the three most recent where ARE is the FILER (not the subject) are Applied Therapeutics (13G/A, 13 Nov 2024), Genetron Holdings Limited (13D/A, 1 Apr 2024, exit filing reporting 0 shares / 0.0% following Genetron's 28 Mar 2024 take-private merger; recorded as a note, not a row, since it is a checked, fully exited position), and GreenLight Biosciences Holdings, PBC (13D, 8 Jun 2023, itself a going-private rollover filing). No SC 13D/G of any kind associated with ARE's CIK, in either direction, has been filed since 13 Nov 2024, nearly two years before this research date (20 Aug 2026); this staleness is flagged on the Applied Therapeutics holdings row.
• The 10-Q's real estate joint venture disclosures (Note 4) were read in full for the JV pct_of_target risk: the unconsolidated JV percentages in this file (10.0% at 1655/1725 Third Street, 58.4% at 101 West Dickman Street) are written as whole-number percentages, not decimals, matching the filing's own '10.0%' / '58.4%' prose. Several additional consolidated JV ownership percentages appear in the 10-Q's consolidation-framework table (30.0%, 10.0%, 48.6%, 30.0%, 30.0%, 60.0% across named properties in San Francisco Bay Area / Seattle submarkets) but no counterparty company name is given for any of them in the sections retrieved, so they were not added as holdings rows; only the Norges Bank JV (50 and 60 Binney Street), where the partner is named and independently identifiable in the proxy and already appears in this file's register, was added.
• Market cap uses the 15 Jul 2026 cover-page share count (174,247,570) and the 19 Aug 2026 Nasdaq quote ($50.55, up 10.27% that session; the quote API itself reports the primary listing as NYSE).
• Register total: 13 rows, raw share sum 102,984,209, self-gate charted total (after de-duplicating the Marcus/officers-group overlap) 102,421,485 shares, 58.78% of shares outstanding (174,247,570). Row count of 13 verified against the actual length of the register array in this file.
• Coordinator verification. The 58.78 per cent self-gate sits above the project's 55 per cent line and was corroborated per holder against this project's own independent 13F-derived snapshot at data/registers/ARE.json plus two proxy denominator back-solves, and the overlap gate reports 0 violations and 0 orphans. Three judgement calls were reviewed and are recorded here so a later reader does not have to re-derive them. First, the combined-balance rule was applied correctly and is the main finding on the holdings side: the combined 'investments in publicly traded companies' balance of $122,812,000 and the combined equity-method balance of $397,445,000 name no investee and were deliberately assigned to NONE, which is the Invesco/Great Wall defect this project records and the single easiest error to make on a venture portfolio. Second, the 59 per cent interest in 50 and 60 Binney Street is DERIVED, not filed: the proxy discloses only the Norges Bank affiliate's 41.0 per cent, and 59 is its arithmetic complement. That is sound only if the venture has exactly two partners, which the proxy does not state outright, so the row is correctly carried at confidence 'estimated' with the derivation spelled out in its own method_note. Treat it as an estimate rather than a filed figure. Third, the Applied Therapeutics row is the only individually sized public stake and it rests on a Schedule 13G/A dated 13 Nov 2024, now roughly 21 months stale. That is acceptable here only because Alexandria files no Form 13F at all, which is the documented exception to preferring a fresh 13F, but the position may since have changed and the row should not be read as current. Norges Bank appears in this file in two unrelated capacities, as a 9.43 per cent holder of ARE common stock via its own 13F and as the 41 per cent partner in the Binney Street venture; these are different instruments and are deliberately kept separate.